REGN Financial Facts

Loss from operations: 362.8M
Cost of goods sold: 29.9M
See Full Income Statement

Accumulated other comprehensive loss: -2.9M
Deferred revenue from Sanofi: 529.79M
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/21 *Est. EPS Growth Rate +49.8% *Last Qtr.
Average EPS % Beat Rate +15.0% Revenue Growth Rate +38.3% *Last Qtr.
Average % Move 1-Wk after EPS -2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
5/7/19 Q119 $4.45$5.46 -$1.01$1.71B$1.76B N/A Details
2/9/16 Q415 $2.83$3.31 -$0.48$1.1B$1.17B N/A Details
5/8/14 Q114 $0.58$0.94 -$0.36$626M$609.04M N/A Details
7/28/11 Q211 -$0.69-$0.41 -$0.28$107.8M$121.51M N/A Details
5/4/17 Q117 $2.92$3.07 -$0.15$1.32B$1.3B = Details
5/3/11 Q111 -$0.49-$0.36 -$0.13$112.2M$117.02M N/A Details
11/4/14 Q314 $2.52$2.57 -$0.05$726M$733.04M N/A Details
5/5/16 Q116 $2.57$2.58 -$0.01$1.2B$1.18B N/A Details